Form 4: Protara Therapeutics Executive Leonardo Nicacio Acquires Shares and Stock Options

Leonardo Nicacio, Chief Medical Officer of Protara Therapeutics, reports acquisition of 50,000 shares of common stock and 150,000 stock options.

Summary

• On April 15, 2025, Leonardo Nicacio, the Chief Medical Officer of Protara Therapeutics, acquired 50,000 shares of common stock through restricted stock units (RSUs) and 150,000 stock options.
• The RSUs vest in equal one-third installments annually starting April 15, 2025.
• The stock options, with an exercise price of $4.17, vest 25% on the one-year anniversary of April 15, 2025, and then 1/48th monthly over the subsequent three years, contingent upon continuous service.
• Following these transactions, Nicacio beneficially owns 52,181 shares of common stock and 150,000 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock and option grants. The insider's increased stake could be mildly positive.

Positives

• The acquisition of shares and stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the increased ownership by a key executive as a positive signal.

Key Dates

Keywords

Protara Therapeutics, Leonardo Nicacio, stock options, RSUs, common stock, beneficial ownership, Form 4, TARA